Searchable abstracts of presentations at key conferences on calcified tissues

ba0002oc26 | Chronic diseases | ICCBH2013

Vertebral fractures in the 3-year period following steroid initiation among children with chronic illnesses

Miettunen P M , Taljaard M , Alos N , Atkinson S , Cabral D , Clarson C , Couch R , Cummings E A , Feber J , Grant R M , Lentle B , Matzinger M , Nadel H , Rodd C , Shenouda N , Stein R , Stephure D , Taback S , Rauch F , Siminoski K , Ward L M , the Canadian STOPP Consortium

Objectives: To describe the incidence of vertebral fractures in steroid-treated children.Methods: Fractures were assessed prospectively each year for 3 years according to the Genant semi-quantitative method. Proportions of children with incident fractures were determined annually over the study period. To examine associations with baseline clinical factors, the 3-year total number of incident fractures was analyzed using multivariable Poisson regression....

ba0007p164 | (1) | ICCBH2019

Musculoskeletal deficits persist up to two years despite anti-TNF-alpha antibody therapy in children with Crohn's disease: Results of a prospective, observational inception cohort study

Jackowski Stefan A , Ma Jinhui , Benchimol Eric I , Rauch Frank , Leonard Mary B , Zemel Babette S , Matzinger Mary Ann , Shenouda Nazih , Lentle Brian , Jaremko Jacob L , Khatchadourian Karine , Robinson Marie-Eve , Konji Victor N , Siminoski Kerry , Mack David , Ward Leanne M

Objectives: To evaluate musculoskeletal trajectories in children with newly diagnosed Crohn’s disease (CD), and to determine whether children treated with anti-tumour necrosis factor-alpha antibody (anti-TNF, TREATED vs NAÏVE) had persistent deficits at two years.Methods: This was a single-centre prospective, observational inception cohort study. Children with CD underwent assessments within 6.5±9.5 days from diagnosis and annually for two...

ba0005oc2.6 | Bone mass and bone strength Wnt signalling | ECTS2016

N-cadherin maintains osteoprogenitor number and restrains Wnt signaling in osteoblasts

Fontana Francesca , Salazar Valerie , Brecks Cynthia , Revollo Leila , Mbalaviele Gabriel , Civitelli Roberto

We have shown that genetic ablation of Cdh2 (N−cadherin gene) in osteolineage cells results in osteopenia and decreased osteoprogenitor number. Paradoxically, others have shown that mice overexpressing Cdh2 in osteoblasts are also osteopenic; an action linked to a negative effect of N−cadherin (Ncad) on Wnt signaling, via sequestration of low density lipoprotein receptor−related protein−...

ba0001pp180 | Cell biology: osteoblasts and bone formation | ECTS2013

N-cadherin governs age-related osteoprogenitor cell determination in mice through modulation of Wnt5a and Wnt10b

Hay Eric , Dieudonne Francois-Xavier , Marty Caroline , Marie Pierre J

Senile osteoporosis and age-related osteopenia are associated with decreased osteoblastogenesis and increased bone marrow adipogenesis. The mechanisms controlling the fate determination of osteoblast to adipocyte differentiation of bone marrow stromal cells (BMSC) during aging are not known. We and others previously showed that the cell-cell adhesion molecule N-cadherin (N-Cadh) expressed in osteoblasts controls bone formation, but little is known about its role in BMSC fate d...

ba0007p46 | (1) | ICCBH2019

Vertebral fractures are more prevalent than long bone fractures in boys with glucocorticoid-treated Duchenne Muscular Dystrophy: Results of a prospective observational study

Jackowski Stefan A , McAdam Laura C , Ma Jinhui , McMillan Hugh J , Konji Victor N , Matzinger Mary Ann , Shenouda Nazih , Jaremko Jacob L , Koujok Khaldoun , Khan Nasrin , Khatchadourian Karine , Robinson Marie-Eve , MacLeay Lynn , Saleh David S , Siminoski Kerry , Rauch Frank , Ward Leanne M

Objectives: Osteoporosis is a frequent cause of morbidity in boys with glucocorticoid (GC)-treated Duchenne Muscular Dystrophy (DMD). We sought to determine the frequency and characteristics of the two most debilitating types of fractures, vertebral and long bone (VF and LBF), in pediatric DMD.Methods: This was a prospective, bi-centre, single-visit observational study in boys 4 to 17 years of age with genetically-confirmed DMD. The bone health assessmen...

ba0003pp163 | Cell biology: osteoclasts and bone resorption | ECTS2014

The molecular mechanism of n-butanol extracts of Panax notoginseng on RANKL-induced osteoclastogenesis in RAW264.7 cells

Hwang Hyo-In , Jang Young-Joo , Ko Seon-Yle

This study examined the anti-osteoclastogenic effect of n-butanol extracts of Panax notoginseng on the receptor activator of NF-kB ligand (RANKL) induced RAW264.7 cells. Panax notoginseng is commonly used to treat chronic liver disease. Notoginseng has many beneficial effects, such as the suppression of liver fibrosis and anti-cancer activities. Notoginseng contains several biologically active components, such as ginsenosides Rb1, Rg1...

ba0003pp114 | Cell biology: osteoblasts and bone formation | ECTS2014

N-linked glycosylation as a critical mechanism of PTH-resistance in osteoblasts in high glucose conditions

Picke Ann-Kristin , Hamann Christine , Rauner Martina , Hofbauer Lorenz C.

Type 2 diabetes mellitus impairs bone quality and increases fracture risk. We showed that diabetic ZDF rats have low bone mass due to impaired osteoblastogenesis, which can be partially reversed with an intermittent parathyroid hormone 1–84 (PTH) therapy. It remains unclear, why PTH treatment does not fully restore osteoblast (OB) function in diabetic conditions. Here, we tested if high glucose (HG) conditions lead to a partial PTH resistance in osteoblasts. Pre-osteoblas...

ba0007p151 | (1) | ICCBH2019

The safety and efficacy of denosumab versus zoledronic acid in the treatment of pediatric osteoporosis: a randomized controlled pilot trial

Robinson Marie-Eve , Ma Jinhui , Khan Nasrin , Khatchadourian Karine , Page Marika , Konji Victor , Ann Matzinger Mary , Shenouda Nazih , Jaremko Jacob L , Zuijdwijk Caroline , Jackowski Stefan , Saleh David , MacLeay Lynn , Siminoski Kerry , Ward Leanne M

Objectives: Denosumab (Dmab) is a monoclonal antibody targeting RANKL administered by sub-cutaneous injection. Given its convenient mode of administration, our goal was to assess the safety and efficacy of Dmab compared to intravenous zoledronic acid (ZA) in pediatric osteoporosis.Methods: In this one-year pilot study (NCT02632916), children 4–16 years with low-trauma fractures due to osteoporosis were randomized 1:1 to receive ZA 0.025 mg/kg or Dma...

ba0007p152 | (1) | ICCBH2019

An evaluation of the rebound phenomenon during denosumab therapy in children with low turnover osteoporosis

Robinson Marie-Eve , Ma Jinhui , Khan Nasrin , Khatchadourian Karine , Page Marika , Konji Victor , Ann Matzinger Mary , Shenouda Nazih , Jaremko Jacob L , Zuijdwijk Caroline , Jackowski Stefan , Saleh David , MacLeay Lynn , Siminoski Kerry , Ward Leanne M

Objectives: Denosumab (Dmab) is a monoclonal antibody targeting RANKL administered by sub-cutaneous injection. Recent reports have raised concern about the ‘rebound phenomenon’ (hypercalcemia and increases in bone turnover markers, BTM) following Dmab in adults, and during treatment in children with osteogenesis imperfecta. The purpose of this report was to explore this phenomenon in children with osteoporosis associated with lower bone turnover.<p class="abstext...

ba0004p187 | (1) | ICCBH2015

TBS increases over time in pre-teen girls

Libber J , Winzenrieth R , Krueger D , Scarpella T , Binkley N

Muscle and loading force application alters bone structure and increases bone mineral density (BMD), particularly during growth. However, bone microarchitectural texture, as assessed by the trabecular bone score (TBS), changes during growth is unknown. We hypothesized that TBS would be positively correlated with growth and higher in growing girls participating in regular physical exercise.68 girls (mean age 12±0.3 years; BMI 18±2.8 kg/m2</...